AU2020409912A1 - Compounds for inhibiting neovascularization factors and use thereof - Google Patents

Compounds for inhibiting neovascularization factors and use thereof Download PDF

Info

Publication number
AU2020409912A1
AU2020409912A1 AU2020409912A AU2020409912A AU2020409912A1 AU 2020409912 A1 AU2020409912 A1 AU 2020409912A1 AU 2020409912 A AU2020409912 A AU 2020409912A AU 2020409912 A AU2020409912 A AU 2020409912A AU 2020409912 A1 AU2020409912 A1 AU 2020409912A1
Authority
AU
Australia
Prior art keywords
compound
chemical formula
hydroxy
alkyl
functional group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020409912A
Other languages
English (en)
Inventor
Byoung Heon Kang
So-Yeon Kim
Changwook Lee
Dong Ho Park
Nam Gu YOON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smartin Bio Inc
UNIST Academy Industry Research Corp
Original Assignee
Smartin Bio Inc
UNIST Academy Industry Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smartin Bio Inc, UNIST Academy Industry Research Corp filed Critical Smartin Bio Inc
Publication of AU2020409912A1 publication Critical patent/AU2020409912A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020409912A 2019-12-16 2020-12-16 Compounds for inhibiting neovascularization factors and use thereof Abandoned AU2020409912A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0168238 2019-12-16
KR20190168238 2019-12-16
PCT/KR2020/018475 WO2021125800A1 (ko) 2019-12-16 2020-12-16 신생혈관형성인자의 억제를 위한 화합물 및 그 용도

Publications (1)

Publication Number Publication Date
AU2020409912A1 true AU2020409912A1 (en) 2022-06-16

Family

ID=76477859

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020409912A Abandoned AU2020409912A1 (en) 2019-12-16 2020-12-16 Compounds for inhibiting neovascularization factors and use thereof

Country Status (9)

Country Link
US (1) US12545695B2 (https=)
EP (1) EP4079309A4 (https=)
JP (1) JP7831775B2 (https=)
KR (1) KR20210076875A (https=)
CN (1) CN114901290B (https=)
AU (1) AU2020409912A1 (https=)
BR (1) BR112022011147A2 (https=)
CA (1) CA3164800A1 (https=)
WO (1) WO2021125800A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901290B (zh) 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途
JP7766885B2 (ja) * 2021-06-15 2025-11-11 スマーティン バイオ インコーポレイテッド Ｔｒａｐ１阻害剤およびその用途
KR102894216B1 (ko) * 2022-12-15 2025-12-18 울산과학기술원 Trap-1 억제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20060229278A1 (en) 1998-11-25 2006-10-12 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
JP4648319B2 (ja) 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
KR20070030815A (ko) 2004-07-13 2007-03-16 오리디스 비오메드 포르슝스-운트 엔트비크룽스 게엠베하 간질환 및 상피암의 치료에서 미토콘드리아적으로 표적화된산화방지제의 용도
US7750018B2 (en) 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
BRPI1014978A2 (pt) 2009-04-17 2019-07-02 Colby Pharmaceutical Company método de tratamento do câncer e composição farmacêutica.
KR101621418B1 (ko) 2014-03-19 2016-05-23 울산과학기술원 미토콘드리아 표적화된 항-종양 조성물
CN114901290B (zh) 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途

Also Published As

Publication number Publication date
WO2021125800A1 (ko) 2021-06-24
JP7831775B2 (ja) 2026-03-17
EP4079309A1 (en) 2022-10-26
CN114901290A (zh) 2022-08-12
US12545695B2 (en) 2026-02-10
KR20210076875A (ko) 2021-06-24
CA3164800A1 (en) 2021-06-24
US20230088747A1 (en) 2023-03-23
EP4079309A4 (en) 2024-01-10
JP2023506838A (ja) 2023-02-20
CN114901290B (zh) 2024-09-03
BR112022011147A2 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
JP6994538B2 (ja) 医薬化合物
KR102740623B1 (ko) Hpk1 억제제 및 이의 사용 방법
TWI571468B (zh) 蛋白質酪胺酸激酶活性抑制劑
CA2766033C (en) Prodrugs of nh-acidic compounds
US12545695B2 (en) Compounds for inhibiting neovascularization factors and use thereof
JP2021535169A (ja) Ｔｅａｄモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体
US11382908B2 (en) Compositions and methods for treating inflammatory bowel disease
WO2016071283A1 (en) Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
TW200940549A (en) Inhibitors of protein tyrosine kinase activity
CA2700824A1 (en) Heterocyclic compounds as crth2 receptor antagonists
KR20170082494A (ko) 결정 형태의 글루타미나아제 억제제
KR20180059544A (ko) 글루타미나제 억제제와 면역-종양학적 약제에 의한 병용 요법
KR20190040302A (ko) 글루타미나제 억제제와의 병용 요법
TW202438069A (zh) 依喜替康衍生物及其抗體藥物偶聯物
WO2021170811A1 (en) Method of treating eye disease using trpv4 antagonists
EP3765460A1 (en) Inhibition of bmp signaling, compounds, compositions and uses thereof
JP7696301B2 (ja) タンパク質分解のための化合物、組成物、および方法
JP2014521642A (ja) α２アドレナリン受容体の調節因子としてのＮ−（イミダゾリジン−２−イリデン）−ヘテロシクロペンタ［ｂ］ピリジン誘導体
JP7834361B2 (ja) 置換４－（［１，２，４］トリアゾロ［１，５－ａ］ピリジン－６－イル）チオフェン－２－カルボキサミド誘導体及びその使用
CN117769559A (zh) Trap1抑制剂及其用途
TW200827343A (en) Novel phenylacetic acid derivative
JP7766885B2 (ja) Ｔｒａｐ１阻害剤およびその用途
TWI881296B (zh) 包含抑制前列腺素ｅ２受體之新穎化合物與抗癌藥物的用於治療癌症之藥學組成物
EP3124024A1 (en) Medicinal composition inhibiting neovascularization proliferation factor
KR20220167944A (ko) Trap-1 억제제의 안과질환 치료 용도

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOUNDS FOR INHIBITING NEOVASCULARIZATION FACTORS AND USE THEREOF

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period